Eli Lilly and Company (BVMF:LILY34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 5.69T +40.6% |
| Revenue (ttm) | 376.90B +47.4% |
| Net Income | 131.86B +127.6% |
| EPS | 146.86 +129.1% |
| Shares Out | n/a |
| PE Ratio | 43.15 |
| Forward PE | 32.97 |
| Dividend | 0.74 (0.35%) |
| Ex-Dividend Date | May 14, 2026 |
| Volume | 8,466 |
| Open | 210.89 |
| Previous Close | 208.80 |
| Day's Range | 207.78 - 212.68 |
| 52-Week Range | 113.00 - 210.37 |
| Beta | 0.52 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug
Innovent Biologics has entered into an agreement that grants it sole commercialization rights for Eli Lilly's breast cancer drug Verzenios in mainland China, the Chinese drugmaker said Tues...
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commerciali...
FDA to Expedite Review of Eli Lilly’s (LLY) New Manufacturing Facilities
The company is spending $27 billion to build four new plants.
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
The U.S. Food and Drug Administration has selected Eli Lilly and Regeneron , among seven companies, for a pilot program to accelerate reviews of new domestic pharmaceutical manufacturing fa...
Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says
Eli Lilly (LLY), Regeneron (REGN), Amneal (AMRX), Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA’s PreCheck pilot progr...
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA's PreCheck pilot program. The FDA PreCheck...
Eli Lilly Stock (LLY) Hits All-Time High as Weight-Loss Drug Sales Accelerate
The company has become the market leader in obesity treatments.
GAME CHANGER: Eli Lilly launches $50 Medicare GLP-1 program
Eli Lilly CEO Dave Ricks joins 'Varney & Co.' to discuss the Trump administration's new Medicare GLP-1 Bridge Program, which will offer eligible seniors access to Lilly weight loss medications for $50...
Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet
Millions of older Americans in Medicare are about to gain access to obesity drugs through Medicare's new Bridge demonstration program for a monthly copay of just $50. But many seniors may be unaware o...
Here’s Why Eli Lilly Stock (LLY) Is Up 6% Today
The company has a diverse portfolio of medications.
GLP-1s linked to smell and taste impairment in diabetes patients
We also report on a potentially simple solution to nausea experienced by cancer patients receiving morphine for pain.
Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage
Novo Nordisk, the maker of Wegovy, introduced its GLP-1 pill for weight loss in early January, while Eli Lilly's pill, Foundayo, began shipping in April. In 2025, nearly half of all large employers co...
Eli Lilly’s Jaypirca recommended by CHMP for approval in EU
Eli Lilly (LLY) and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion for Jaypirca, a non-covalent Bruton tyrosine kin...
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of Hematology Annual Meeting and published in The Jo...
Eli Lilly announces more details of Medicare GLP-1 Bridge program
Eli Lilly (LLY) announced additional details regarding the Medicare GLP-1 Bridge program taking effect July 1. Under the program, Medicare Part D patients may be able to access Foundayo or…
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
A new Medicare pathway, the Medicare GLP-1 Bridge program, makes Lilly's obesity medicines – a daily pill or the number 1 most prescribed injectable – accessible to eligible Medicare Part D patients b...
Eli Lilly price target raised to $1,232 from $1,119 at Leerink
Leerink analyst David Risinger raised the firm’s price target on Eli Lilly (LLY) to $1,232 from $1,119 and keeps an Outperform rating on the shares.
Controversy Erupts Over Report Trump Has Early Access to Eli Lilly (LLY) Weight-Loss Drug
This is not the first controversy involving the U.S. president and drug maker.
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
INDIANAPOLIS, June 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Centessa Pharmaceuticals plc. Centessa is a clinical-stage...
Eli Lilly uses cash pile to fund untested drug development strategies, FT says
Eli Lilly (LLY) will be using its cash pile to fund untested drug development strategies in preparation for the expiration of patents on its weight-loss drugs, Patrick Temple-West of The…
Eli Lilly enters $1.9B research collaboration with Abbisko Therapeutics
Abbisko Therapeutics announced that it has entered into a strategic research collaboration and license agreement with Eli Lilly (LLY). Under the agreement, the two companies will collaborate on the di...
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
Eli Lilly's orforglipron type-2 diabetes and obesity pill could launch in China as soon as later this year, an executive at the U.S. drugmaker told Reuters, as rival Novo Nordisk seeks to catch up i...
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Abbisko Cayman said on Wednesday that its Shanghai-based unit Abbisko Therapeutics has entered into a strategic research collaboration and license agreement with Eli Lilly.
Eli Lilly (LLY) to Launch Weight-Loss Pill in Europe Next Year
The company is waiting on regulatory approvals abroad.